Skip to main content

Chronic Myeloid Leukemia


Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Conference Coverage
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and…
Gary Lyman, MD, Fred Hutchinson Cancer Research Center, discusses a project exploring the cost of TKIs, particularly…
Research Report
Henry J Henk, PhD, and colleagues examined 10-year US trends in TKI treatment selection, switching, adherence, and…
The cost-effectiveness of therapeutic drug monitoring for imatinib administration in CML may fall within an acceptable…
Back to Top